150 related articles for article (PubMed ID: 17886336)
21. Enhanced external counterpulsation: a new technique to augment renal function in liver cirrhosis.
Werner D; Trägner P; Wawer A; Porst H; Daniel WG; Gross P
Nephrol Dial Transplant; 2005 May; 20(5):920-6. PubMed ID: 15788437
[TBL] [Abstract][Full Text] [Related]
22. Differentiated and dose-related cardiovascular effects of a dual endothelin receptor antagonist in endotoxin shock.
Konrad D; Oldner A; Rossi P; Wanecek M; Rudehill A; Weitzberg E
Crit Care Med; 2004 May; 32(5):1192-9. PubMed ID: 15190972
[TBL] [Abstract][Full Text] [Related]
23. Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS).
Teerlink JR; McMurray JJ; Bourge RC; Cleland JG; Cotter G; Jondeau G; Krum H; Metra M; O'Connor CM; Parker JD; Torre-Amione G; Van Veldhuisen DJ; Frey A; Rainisio M; Kobrin I;
Am Heart J; 2005 Jul; 150(1):46-53. PubMed ID: 16084150
[TBL] [Abstract][Full Text] [Related]
24. Influence of liver cirrhosis on the pharmacokinetics, pharmacodynamics, and safety of tezosentan.
Dingemanse J; Halabi A; van Giersbergen PL
J Clin Pharmacol; 2009 Apr; 49(4):455-64. PubMed ID: 19318695
[TBL] [Abstract][Full Text] [Related]
25. Treatment of hepatorenal syndrome as defined by the international ascites club by albumin and furosemide infusion according to the central venous pressure: a prospective pilot study.
Péron JM; Bureau C; Gonzalez L; Garcia-Ricard F; de Soyres O; Dupuis E; Alric L; Pourrat J; Vinel JP
Am J Gastroenterol; 2005 Dec; 100(12):2702-7. PubMed ID: 16393223
[TBL] [Abstract][Full Text] [Related]
26. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure.
Torre-Amione G; Young JB; Colucci WS; Lewis BS; Pratt C; Cotter G; Stangl K; Elkayam U; Teerlink JR; Frey A; Rainisio M; Kobrin I
J Am Coll Cardiol; 2003 Jul; 42(1):140-7. PubMed ID: 12849674
[TBL] [Abstract][Full Text] [Related]
27. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems.
Guevara M; Ginès P; Bandi JC; Gilabert R; Sort P; Jiménez W; Garcia-Pagan JC; Bosch J; Arroyo V; Rodés J
Hepatology; 1998 Aug; 28(2):416-22. PubMed ID: 9696006
[TBL] [Abstract][Full Text] [Related]
28. Effects of the endothelin-1 receptor antagonist tezosentan on renal blood flow and diuresis during prolonged increased intra-abdominal pressure.
Gudmundsson FF; Viste A; Myking OL; Grong K; Bostad L; Svanes K
J Surg Res; 2003 Nov; 115(1):33-40. PubMed ID: 14572770
[TBL] [Abstract][Full Text] [Related]
29. Additional effects of endothelin receptor blockade and angiotensin converting enzyme inhibition in rats with chronic heart failure.
Qiu CB; Qiu CS; Hess P; Clozel JP; Clozel M
Acta Pharmacol Sin; 2001 Jun; 22(6):541-8. PubMed ID: 11747762
[TBL] [Abstract][Full Text] [Related]
30. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials.
McMurray JJ; Teerlink JR; Cotter G; Bourge RC; Cleland JG; Jondeau G; Krum H; Metra M; O'Connor CM; Parker JD; Torre-Amione G; van Veldhuisen DJ; Lewsey J; Frey A; Rainisio M; Kobrin I;
JAMA; 2007 Nov; 298(17):2009-19. PubMed ID: 17986694
[TBL] [Abstract][Full Text] [Related]
31. [Successful conservative therapy of hepatorenal syndrome with vasopressin-1-receptor antagonist ornipressin].
Gülberg V; Luppa P; Pauletzki J; Paumgartner G; Gerbes AL
Z Gastroenterol; 1998 Dec; 36(12):1053-8. PubMed ID: 10025057
[TBL] [Abstract][Full Text] [Related]
32. Tezosentan in the management of decompensated heart failure.
Cheng JW
Cardiol Rev; 2005; 13(1):28-34. PubMed ID: 15596026
[TBL] [Abstract][Full Text] [Related]
33. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion.
Guevara M; Ginès P; Fernández-Esparrach G; Sort P; Salmerón JM; Jiménez W; Arroyo V; Rodés J
Hepatology; 1998 Jan; 27(1):35-41. PubMed ID: 9425914
[TBL] [Abstract][Full Text] [Related]
34. Tezosentan in the treatment of acute heart failure.
Tovar JM; Gums JG
Ann Pharmacother; 2003 Dec; 37(12):1877-83. PubMed ID: 14632537
[TBL] [Abstract][Full Text] [Related]
35. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response.
Sharma P; Kumar A; Shrama BC; Sarin SK
Am J Gastroenterol; 2008 Jul; 103(7):1689-97. PubMed ID: 18557715
[TBL] [Abstract][Full Text] [Related]
36. Terlipressin therapy for renal failure in cirrhosis.
Triantos CK; Samonakis D; Thalheimer U; Cholongitas E; Senzolo M; Marelli L; Leandro G; Patch D; Burroughs AK
Eur J Gastroenterol Hepatol; 2010 Apr; 22(4):481-6. PubMed ID: 19952764
[TBL] [Abstract][Full Text] [Related]
37. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome.
Nazar A; Pereira GH; Guevara M; Martín-Llahi M; Pepin MN; Marinelli M; Solá E; Baccaro ME; Terra C; Arroyo V; Ginès P
Hepatology; 2010 Jan; 51(1):219-26. PubMed ID: 19877168
[TBL] [Abstract][Full Text] [Related]
38. Effects of endothelin-1 and endothelin-1-receptor blockade on renal function in humans.
Vuurmans JL; Boer P; Koomans HA
Nephrol Dial Transplant; 2004 Nov; 19(11):2742-6. PubMed ID: 15328386
[TBL] [Abstract][Full Text] [Related]
39. The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites.
Kalambokis G; Economou M; Fotopoulos A; Al Bokharhii J; Pappas C; Katsaraki A; Tsianos EV
Am J Gastroenterol; 2005 Apr; 100(4):879-85. PubMed ID: 15784036
[TBL] [Abstract][Full Text] [Related]
40. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond.
Moreau R; Lebrec D
Hepatology; 2006 Mar; 43(3):385-94. PubMed ID: 16496352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
